In Vitro Activity of New Cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008–2011 by Karen Green et al.
In Vitro Activity of New Cephalosporins vs Streptococcus
pneumoniae from the Canadian Bacterial Surveillance Network:
2008–2011
Karen Green • Allison McGeer • Wallis Rudnick •
Sylvia Pong-Porter • Samir N. Patel • Donald E. Low •
The Canadian Bacterial Surveillance Network (CBSN)
Received: 27 February 2014 / Accepted: 18 April 2014 / Published online: 15 July 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Between 2008 and 2011, 6,895 Streptococcus
pneumoniae isolates were submitted to the Canadian Bac-
terial Surveillance Network and underwent in vitro sus-
ceptibility testing. Fifteen percent of S. pneumoniae
isolates were collected from pediatric patients (0–15 years
old), 48.6 % of isolates were collected from adults between
16 and 64 years of age, and 36.1 % from adults aged
C65 years; age data were not available for 11 patients.
Forty-five percent of S. pneumoniae isolates were recov-
ered from sterile specimens, and 55 % of isolates were
from nonsterile specimens. Overall, 0.4 % of isolates were
resistant to penicillin, 0.4 % to ceftriaxone, 3 % to amox-
icillin, 25 % to erythromycin, and 13 % to trimethoprim/
sulfamethoxazole; 6.6 % of isolates were multidrug resis-
tant (MDR). Among MDR isolates, resistance rates
exceeded 95 % for erythromycin, tetracycline, and tri-
methoprim/sulfamethoxazole. The MIC90 of cethromycin,
ceftaroline, and ceftobiprole against MDR isolates were
0.12, 0.25, and 1 mg/L, respectively. Ceftaroline, the active
form of the prodrug ceftaroline fosamil, exhibited potent
in vitro activity against the tested S. pneumoniae including
all 456 multidrug-resistant strains. No ceftaroline-resistant
isolates were identified.
Introduction
Streptococcus pneumoniae is the most common bacterial
pathogen associated with community-acquired bacterial
pneumonia (CABP) [10, 14]. The use of pneumococcal
conjugate vaccines has decreased the incidence of invasive
pneumococcal disease. However, the number of strains that
are resistant to commonly used antibiotics continues to
increase [6].
Ceftaroline, the active form of the prodrug ceftaroline
fosamil, is a parenteral cephalosporin exhibiting broad
spectrum in vitro bactericidal activity against gram-posi-
tive pathogens, including multidrug-resistant (MDR) S.
pneumoniae and methicillin-resistant Staphylococcus aur-
eus, and common gram-negative organisms [5, 12, 15].
Ceftaroline fosamil is approved in the United States for the
treatment of patients with CABP and acute bacterial skin
and skin structure infections and for similar indications in
Europe [16, 18]. We previously demonstrated that ceftar-
oline was the most active b-lactam agent tested against a
subset of 260 MDR S. pneumoniae isolates collected across
Canada between 2003 and 2008 [13].
The Canadian Bacterial Surveillance Network (CBSN)
has collected S. pneumoniae isolates as part of a nation-
wide surveillance program since 1988. In recent years,
there has been not only an increase in the prevalence of
MDR S. pneumoniae, but also an increase in the degree of
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resistance to the b-lactam antibiotics. Surveillance studies
in the United States also indicate an increase in nonsus-
ceptibility of S. pneumoniae to common b-lactam antibi-
otics [6, 7]. The objective of this study was to assess the
in vitro activity of ceftaroline and comparative agents
against CBSN S. pneumoniae isolates collected from 2008
to 2011.
The CBSN encompasses volunteer community and
hospital-affiliated laboratories across Canada, which pro-
vide services to community and tertiary-care hospitals,
community clinics, physician offices, and long-term care
facilities. All ten Canadian provinces and two of three
territories are represented. In total, 186 laboratories have
participated in the CBSN, with 40 laboratories submitting
annually since 1993. Only one isolate per patient episode is
included; laboratories are asked to submit all sterile-site
isolates and a defined number of consecutive nonsterile-site
isolates annually, based on laboratory size. All isolates are
submitted to a central laboratory where they are confirmed
as S. pneumoniae and serotyped using latex antisera (Sta-
tens Serum Institute, Denmark) and Quellung reaction [17].
Isolates that cannot be serotyped at the central laboratory
are serotyped at Canada’s National Microbiology Labora-
tory. Broth microdilution susceptibility testing is per-
formed and interpreted according to the Clinical and
Laboratory Standards Institute (CLSI) guidelines [1]. For
this study, nonmeningeal breakpoints for ceftaroline, pen-
icillin, amoxicillin, and ceftriaxone are used to interpret
MIC results [1]. In addition, an analysis by meningeal
breakpoints was included to determine resistant isolates to
penicillin and ceftriaxone.
From 2008 to 2011, 6,895 S. pneumoniae isolates from
59 centers underwent antimicrobial susceptibility testing.
There were 1,043 (15.1 %) isolates collected from pediat-
ric patients (0–15 years old), 3,350 (48.6 %) isolates col-
lected from adults between 16 and 64 years of age, and
2,491 (36.1 %) from adults aged C65 years; age data were
not available for 11 patients. Of 6,895 isolates, 3,088
(45 %) were recovered from sterile specimens (2,868
blood, 76 cerebral spinal fluid, 63 pleural fluid, and 81
other), and 3,796 (55 %) isolates were from nonsterile
specimens (2,572 sputum, 417 eye, 247 ear, and 560 other).
Among sterile-site isolates, the most common serotypes
were 19A (17 %), 7F (13 %), and 3 (8 %). Among non-
sterile-site isolates, the most common serotypes isolated
were 19A (11 %), 3 (9 %), and 11A (9 %). There were
decreases in many common serotypes following the
introduction of PCV10 in some provinces in 2009 and
PCV13 in 2010. Serotypes included in PCV10 (1, 4, 5,
6B, 7F, 9 V, 14, 18C, 19F, 23F) and PCV13 (all in
Fig. 1 Percent of isolates
nonsusceptible to common
antibiotics and multidrug-
resistant (MDR) isolates by
year, 2008–2011.
*MDR = multidrug-resistant,
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PCV10 and 3, 6A, 19A) accounted for 53.9 % of
isolates in 2008, but this decreased to 44.6 % of isolates
in 2011.
The proportion of isolates resistant to more than two
classes of antibiotics (MDR isolates) increased over time
(Fig. 1). Overall, 6.6 % (456/6,895) of pneumococcal iso-
lates were MDR. Among MDR isolates, resistance rates
exceeded 95 % for erythromycin, tetracycline, and tri-
methoprim/sulfamethoxazole (Table 1). The MIC90 of ce-
thromycin, ceftaroline, and ceftobiprole against MDR
isolates were 0.12, 0.25, and 1 mg/L, respectively (Table 2).
The highest MICs observed for ceftaroline, ceftobiprole, and
cethromycin were 0.5, 2, and 4 mg/L, respectively.
The MIC90 of ceftaroline was C8-fold lower, the MIC90
of ceftobiprole was C2-fold lower, and the MIC90 of ce-
thromycin was C16-fold lower than the MIC90 of ceftri-
axone across penicillin-, amoxicillin-, or erythromycin-
resistant isolates and in MDR isolates (Table 3). The
MIC90 of ceftriaxone increased over the study period from
0.25 mg/L in 2008 to 0.5 mg/L in 2011 (data not shown).
Additionally, among all isolates, 13.2 % demonstrated
high-level erythromycin resistance (MIC C16 mg/L) and
12.0 % demonstrated low-level erythromycin resistance
(MIC C1 to \16 mg/L) (Table 1).
Table 1 Percent of resistant Streptococcus pneumoniae isolates from
Canada, 2008–2011





[n/N = 6.6 %]
Penicillin (nonmeningitis) 0.4 6.1
Penicillin (meningitis) 18.6 87.1
Amoxicillinb 3.4 51.1
Ceftriaxone (nonmeningitis) 0.4 6.1







a MDR multidrug-resistant, resistant to [2 classes of antibiotics
(classes: b-lactams [penicillin/amoxicillin/ceftriaxone], erythromycin,
tetracycline, trimethoprim/sulfamethoxazole, ciprofloxacin)
b Nonmeningeal breakpoints used
c High-level erythromycin resistance = MIC C16 mg/L; low-level
erythromycin resistance = MIC C1 to \16 mg/L
Table 2 In vitro activities of antimicrobial agents against multidrug-resistant Streptococcus pneumoniae isolates from Canada, 2008–2011
(N = 456)
MIC (mg/L) N (% of isolates)
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Bolded values = MIC90; gray boxes = intermediate MIC values as defined by CLSI
a Nonmeningeal breakpoints
b MIC susceptibility breakpoint: B0.5 mg/L
c MIC breakpoints not established by CLSI
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Emerging S. pneumoniae resistance, particularly for
macrolides, is evident based on these surveillance data and
reports from SENTRY [6]. High-level macrolide resistance
is increasing, with more than half of erythromycin-resistant
isolates considered to have high-level resistance in this
study. Guidelines may no longer be able to recommend
macrolides for first-line therapy based on[25 % resistance
levels [9]. Resistance to b-lactam agents, apart from cef-
taroline, also increased throughout the study period.
Ceftaroline, ceftobiprole, and cethromycin exhibited
more potent in vitro activity against MDR pneumococci
than ceftriaxone. Potent in vitro activity of ceftaroline
against pneumococci has also been reported from the
Assessing Worldwide Antimicrobial Resistance Evalua-
tion (AWARE) program [4]. In vitro activity of ceftaro-
line can be attributed to its high affinity for S.
pneumoniae penicillin-binding proteins (PBPs), including
PBPs 1a, 2b, and 2x [8, 11]. In an integrated analysis of 2
phase 3 clinical trials comparing ceftaroline fosamil with
ceftriaxone in the treatment of patients with CABP,
clinical cure at the test-of-cure visit was higher in the
ceftaroline fosamil group than in the ceftriaxone group in
patients with S. pneumoniae (85.5 vs 68.6 %, respec-
tively) [3]. An analysis of patients in these trials that
evaluated clinical response rates at an earlier end point,
72 h after initiation of therapy, showed similar results,
with 73 % of patients in the ceftaroline fosamil group
compared with 56 % of patients in the ceftriaxone group
experiencing clinical response following a S. pneumoniae
infection (P = 0.03) [2].
In summary, the percentage of MDR S. pneumoniae iso-
lates increased from approximately 5 % in 2008 to 8 % in
2011. Among the b-lactam antibiotics tested, ceftaroline
demonstrated the most potent in vitro activity against MDR S.
pneumoniae. The highest MIC observed for ceftaroline
against any S. pneumoniae isolate was 0.5 mg/L. These data
suggest that ceftaroline fosamil can play an important role in
the treatment of infection caused by S. pneumoniae, including
MDR strains. Based on the high clinical and microbiological
response rates in clinical trials and the potent in vitro activity
against S. pneumoniae in this analysis, ceftaroline fosamil is a
useful option for management of CABP.
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Appendix
L.P. Abbott, Dr. Everett Chalmers Regional Hospital,
Fredericton, New Brunswick; H. Almohri, Lifelabs Medi-
cal Laboratory Services, Ontario; M. Alfa, St. Boniface
General Hospital, Winnipeg, Manitoba; A. Belhaj, Rouge
Valley Health System, Toronto, Ontario; J. Blondeau,
Royal University Hospital, Saskatoon, Saskatchewan; L.
Bocci, Chaleur Regional Hospital, Bathurst, New Bruns-
wick; W. Ciccotelli, Grand River Hospital, Kitchener,
Ontario; R. Davidson and K. Forward, QEII Elizabeth
Health Sciences Centre, Halifax, Nova Scotia; H.R. Devlin,
St. Michael’s Hospital, Toronto, Ontario; J. Downey,
Toronto East General Hospital, Toronto, Ontario; S. El-
Bailey, Saint John Regional Hospital, Saint John, New
Brunswick; G. German, Queen Elizabeth Hospital,













MIC Ceftriaxone Ceftaroline Ceftobiprole Cethromycin
(mg/L) (N) MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
Penicillin
\8 (6867) 0.25 0.25 0.06 0.06 0.016 0.25 0.016 0.06
C8 (28) 4 8 0.25 0.5 1 1 0.12 0.25
Amoxicillin
\8 (6660) 0.25 0.25 0.06 0.06 0.016 0.06 0.016 0.03
C8 (235) 2 4 0.25 0.25 0.5 1 0.12 0.12
Erythromycin
\ 1 (5164) 0.25 0.25 0.06 0.06 0.016 0.03 0.016 0.016
C1 (1731) 0.25 2 0.06 0.25 0.03 0.5 0.03 0.12
MDR
No (6439) 0.25 0.25 0.06 0.06 0.016 0.06 0.016 0.03
Yes (456) 2 2 0.12 0.25 0.5 1 0.06 0.12
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Charlottetown, Prince Edward Island; H. Giang, Ross
Memorial Hospital, Lindsay, Ontario; D. Hoban and G.
Zhanel, Health Sciences Centre, Winnipeg, Manitoba; Y.
Hussein, Cape Breton Regional Hospital, Sydney, Nova
Scotia; K. Katz, North York General Hospital, North York,
Ontario and Shared Hospital Laboratory Inc, Toronto,
Ontario; P.C. Kibsey, Royal Jubilee Hospital, Victoria,
British Columbia and Nanaimo District General Hospital,
Nanaimo, British Columbia; S. Krajden, St. Joseph’s
Health Centre, Toronto, Ontario; M. Kuhn, The Moncton
Hospital, Moncton, New Brunswick; P.R. Laberge, Centre
Hospitalier Regional de Sept-Iles, Sept-Iles, Quebec; K.S.
Lee, Humber River Regional Hospital, Toronto, Ontario;
B. Nash, Whitehorse General Hospital, Whitehorse,
Yukon; D. Noria, The Scarborough Hospital, Toronto,
Ontario; K. Ostrowska and A. Sarabia, Trillium Health
Partners, Toronto, Ontario; P. Pieroni, Westman Regional
Laboratory, Brandon, Manitoba; R. Price, Royal Victoria
Hospital, Barrie, Ontario; N. Rau, Halton Healthcare,
Oakville, Ontario; D. Richardson, William Osler Health
Services, Brampton, Ontario and Headwaters Health Care
Centre, Orangeville, Ontario; S. Richardson, Hospital for
Sick Children, Toronto, Ontario; V. Sales, Markham Sto-
uffville Hospital, Markham, Ontario; A.E. Simor, Sunny-
brook Health Sciences Centre, Toronto and Lakeridge
Health, Oshawa, Ontario; G. Tyrrell, Alberta Provincial
Health Laboratory, Edmonton, Alberta.
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